Stock Report

All about this stock under one free report Last Updated: 05-Oct-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Protagonist Therapeutics (PTGX) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$140.06

up-down-arrow $0.87 (0.63%)

As on 02-Oct-2026 16:26EDT

Market cap

info icon

$9,063 Mln

Revenue (TTM)

info icon

$282 Mln

P/E Ratio

info icon

134.7

P/B Ratio

info icon

10.7

Div. Yield

info icon

0 %

Edit peer-selector-edit
Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Market cap ($ Mln)
 9,063 16,732 14,995 14,468 12,469
Revenue ($ Mln)
 282 2,782 1,054 2,436 1,664
Net Profit ($ Mln)
 82.91 491.50 755.85 860.62 413.60
Net Margin (%)
 29.40 17.67 71.69 35.33 24.86
RoE (%)
 11.39 110.09 -- 42.98 430.03
Price to Earnings
 134.67 35.22 17.89 18.36 31.39
Price-To-Book
 10.67 39.70 8.91 7.82 88.91

Income Statement ($ Mln)

Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Operating Revenue arrow
281.99 2,782.29 1,054.37 2,435.92 1,663.74
Cost of Revenue arrow
0.78 1,982.07 103.47 85.67 363.07
Gross Profit arrow
44.79 760.62 588.53 2,236.43 1,091.18
Operating Expenses arrow
223.24 216.81 841.45 1,378.74 356.18
Operating Profit (EBIT) arrow
58.34 583.40 109.45 971.51 944.49
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
84.34 598.92 101.11 1,035.47 583.34
Provision for Tax arrow
1.43 107.42 -654.74 174.84 169.74
Profit after Tax (Net Income) arrow
82.91 491.50 755.85 860.62 413.60
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 0.00 0.00 0.00 0.00

Liabilities ($ Mln)

Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Shareholder's Funds arrow
841.54 433.86 1,435.90 1,843.76 143.54
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
6.82 187.89 384.48 288.55 2,089.43
Current Liabilities arrow
37.18 1,435.43 464.70 361.93 344.44
Total Liabilities arrow
669.89 1,975.47 1,302.02 2,844.42 2,525.32

Assets ($ Mln)

Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Non-Current Assets arrow
78.40 1,006.90 895.24 1,243.41 1,644.38
Current Assets arrow
807.15 1,050.29 1,389.84 1,250.82 933.02
Total Assets arrow
669.89 1,975.47 1,302.02 2,844.42 2,525.32
Total Debt* arrow
9.22 120.10 449.89 165.93 2,146.65
Net Current Assets arrow
769.97 -385.14 925.52 888.90 588.59

Cashflow ($ Mln)

Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Cash From Operating Activities arrow
57.67 713.22 51.77 884.27 651.56
Cash Flow from Investing Activities arrow
-49.33 -31.14 -8.15 350.44 -545.81
Cash from Financing Activities arrow
22.86 -860.39 34.89 -969.59 -85.17
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
ROCE (%) arrow
-19.85 53.56 -30.01 32.82 15.61
ROE (%) arrow
11.39 110.09 163.18 42.98 430.03
ROA (%) arrow
9.89 15.64 31.68 29.32 16.19
EBIT Margin (%) arrow
27.66 21.13 5.73 41.23 36.28
Net Margin (%) arrow
29.40 17.67 71.69 35.33 24.86
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Revenue Growth (%) arrow
34.81 24.67 114.85 9.23 41.15
EBIT Growth (%) arrow
45.02 18.70 136.39 27.56 -14.99
Net Profit Growth (%) arrow
59.32 17.50 378.76 42.89 -25.78
EPS Growth (%) arrow
44.83 26.84 353.27 50.42 -23.48
Book Value Growth (%) arrow
12.68 164.02 816.12 -0.70 -55.81

Valuation Ratios

 Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Price / Earnings arrow
-42.66 36.06 -59.76 15.79 24.99
Price / Book Value arrow
9.03 35.44 -80.42 5.72 162.23
Dividend Yield (%) arrow
-- -- -- -- --
EV/EBITDA arrow
-39.00 28.08 -121.54 12.44 17.31
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Debt to Equity arrow
0.00 0.00 0.27 0.00 13.50
Short term debt to equity ratio arrow
0.00 0.00 0.05 0.00 1.46
Current Ratio arrow
21.71 0.73 2.99 3.46 2.71
Quick Ratio arrow
21.71 0.73 2.32 3.38 2.31
Interest Coverage arrow
-- -- 1.62 -- 29.73

Operating Efficiency Ratios

 Protagonist Therapeutics (PTGX) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Halozyme Therapeutics (HALO)
Debtors to sales (%) arrow
4.76 15.88 21.25 13.74 27.40
Asset Turnover arrow
0.34 0.89 0.44 0.83 0.65
Receivable days arrow
686.53 50.42 85.52 43.48 98.04
Inventory Days arrow
-- -- 1,056.70 96.17 190.34
Payable days arrow
1,036.71 6.26 331.01 147.97 18.62
Cash Conversion Cycle arrow
-- -- 811.21 -8.32 269.75
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...